In fact, cholinesterases’ inhibition, AChE and, to some extent butyrilcholinesterase (BChE), are the current therapeutic strategies to manage neurodegenerative disorders such as Alzheimer’s disease by directly improving cholinergic tone (increasing acetylcholine neurotransmitter) and by the less understood long-term anti-neurodegenerative activity [25]. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.